Please ensure Javascript is enabled for purposes of website accessibility

Why Amgen Stock Sailed Through March Without a Scratch

By George Budwell - Apr 2, 2020 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amgen was one of the few blue chip stocks to post a gain during the month of March. Here's why.

What happened

While the broader markets took a historic beating during the month of March, shares of the biotech heavyweight Amgen (AMGN 0.02%) actually gained a modest 1.5% last month, according to data from S&P Global Market Intelligence.

To put the biotech's monthly performance into the proper context, the Dow Jones Industrial Average, the NASDAQ Composite Index, and the S&P 500 all lost more than 10% of their value in March. Amgen, in fact, was one of the only blue chip stocks to exit March in positive territory. 

A pink piggybank floating at sea in a life preserver.

Image source: Getty Images.

So what

Amgen's stock was likely immune to the COVID-19-induced sell-off over the course of March for three core reasons:

  1. Over the first two months of the year, Amgen's stock had already lost a jaw-dropping 17.1% of its value, which essentially erased a full year's worth of gains and transformed the company into a strong value play. 
  2. Early on in March, Amgen announced that it didn't anticipate any major disruptions to its global supply chain as a result of the COVID-19 pandemic. Hence, shareholders shouldn't fret about potential shortages of top-selling drugs. 
  3. With an annualized dividend yield of 3.16% and a resilient revenue stream, Amgen was probably a top pick by investors on the hunt for a safe haven during last month's marketwide downturn. 

Now what

As the COVID-19 pandemic isn't expected to peter out for at least another two full months, investors will definitely want to rotate into high-quality companies that pay a solid dividend and that can still earn money in this unprecedented environment. Amgen, for its part, ticks off both of these all-important boxes. As such, investors can probably expect a repeat performance from this blue chip biotech stock in April and beyond.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
$248.39 (0.02%) $0.04
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$33,761.05 (1.27%) $424.38
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
$13,047.19 (2.09%) $267.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.